Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2004 Mar;23(3):189-97.
doi: 10.1097/01.inf.0000116292.46143.d6.

Safety and efficacy of trivalent inactivated influenza vaccine in young children: a summary for the new era of routine vaccination

Kenneth M Zangwill  1 , Robert B Belshe
Affiliations
Review

Safety and efficacy of trivalent inactivated influenza vaccine in young children: a summary for the new era of routine vaccination

Kenneth M Zangwill et al. Pediatr Infect Dis J. 2004 Mar.

Abstract

Increasing use of influenza vaccine in children is expected as this important virus becomes more widely recognized as a major cause of morbidity in young children. Clinicians and third party payers must consider the implications of national vaccine use recommendations, with their current focus on young children, on their practices and on the community at large. Two influenza vaccines are available in the United States, an inactivated, trivalent intramuscular formulation (TIV) which is approved for use among children > or =6 months of age; and a live, attenuated intranasal trivalent preparation (LAIV) indicated for healthy persons 5 to 49 years of age. This review summarizes available data regarding the safety and efficacy of TIV, in comparison with LAIV, with particular attention to children <9 years of age, the population for whom two doses of vaccine are recommended for first time vaccination. It is apparent that relatively few data are available on the safety of TIV in young children, that important age-specific differences in TIV vaccine efficacy exist and that LAIV appears similar to TIV with regard to safety and efficacy in younger children, but no head-to-head comparison of these two licensed products is available.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

Publication types

MeSH terms